OrthoPediatrics Q3 2026 revenue rises 19% to $72.7 million
OrthoPediatrics reported Q3 2026 revenue up 19% to $72.7 million, a narrower net loss and a raised full-year revenue forecast of $270-273 million.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
OrthoPediatrics, a maker of orthopedic products for children, reported third-quarter 2026 revenue of $72.7 million, up 19% from a year earlier. TradingView, citing documents filed with the SEC, published the figures. The net loss narrowed to $5.9 million from $11.8 million, gross margin stood at 74%, and adjusted diluted loss per share was $0.23.
The company also raised its 2026 revenue guidance to a range of $270 million to $273 million. Adjusted EBITDA rose to $6.9 million from $6.2 million. According to the company, its products helped nearly 42,000 children during the quarter. It additionally announced the full market release of several systems and limited launches of new products.
why it matters
For markets, this is a report from a small medical device company, so its reach beyond its own shareholders is limited. Revenue growth alongside a smaller loss and a higher forecast points to improving operations, while a steady 74% gross margin suggests pricing discipline has held. Investors will likely watch how the company delivers on its new guidance in coming quarters.
tags
instruments
sources
- OrthoPediatrics Posts 19% Revenue Growth to $72.7 Million in Q3 2026 — TradingView, 27 October 2026 at 20:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗